OnBioVC NEWS:

- OnBioVC Announces Beta Launch of Service
- OnBioVC INDEX(TM) Updated thru DEC 2009
- OnBioVC 2009 Year-in-Review, now available
- OnBioVC 1Q10 Trend Analysis, coming soon

SEARCH THE OnBioVC DATABASE:

09

Jun

2009

NovImmune, SA: Series C $54.8M

Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Antibody, X - Diabetes, X - Immunology, X - Inflammation

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on therapeutic monoclonal antibodies for inflammatory diseases and immune related disorders, closed a $54.8M series C financing. Participants include BZ Bank Aktiengesellschaft.

Venture Capital Investors
5AM Ventures Abingworth Management ARCH Venture Partners Aurora Funds Bay City Capital Bessemer Venture Partners Burrill & Co. Chicago Growth Partners CHL Medical Partners Clarus Ventures Credit Agricole Private Equity Delphi Ventures DeNovo Ventures Domain Associates Edmond de Rothschild Investment Partners Essex Woodlands Health Ventures Forbion Capital Partners Foundation Medical Partners HBM Bioventures Imperial Innovations Interwest Partners Kleiner Perkins Life Sciences Partners MedVenture Associates MPM Capital MVM Life Science Partners New Enterprise Associates Novartis Venture Fund Novo Ventures Oxford Bioscience Partners Oxford Finance Polaris Venture Partners Quaker BioVentures Sanderling Ventures Scale Venture Partners SV Life Sciences Texas Emerging Technology Fund Third Rock Ventures Thomas McNerney Partners TPG Growth Venrock Ventech Versant Ventures Wellcome Trust

OnBioVC Friends

IguanaBio
EyeOnFDA
Patent Baristas
Pharma's Cutting Edge
MedTechIQ
The Antibody Blog
BioJobBlog

OnBioVC Partners